Isis Pharmaceuticals Company Profile
Isis Pharmaceuticals, Inc. is a leading drug discovery and development company, focused exclusively on the therapeutic target, RNA. Founded in 1989, Isis' mission is to develop products from its RNA-based technologies, such as antisense. Very little was known about antisense when the Company was first established, but its founders envisioned an opportunity to revolutionize the pharmaceutical industry with a more efficient and targeted means of drug discovery. Since then, Isis scientists have made tremendous progress advancing the science of antisense, unveiling capabilities that have far exceeded their expectations. Antisense drugs are the first class of drugs targeted to control expression of genes through interactions with RNA. The goal of antisense drugs is to intervene at the RNA level to prevent the production of proteins involved in disease. Antisense drugs are designed to complement and bind (hybridize) to a segment of messenger RNA (mRNA) to form a duplex. mRNA contains instructions to make proteins, including those involved in disease. The formation of this duplex or two stranded molecule prevents the RNA from functioning normally and from producing a specific protein. Antisense drugs are designed to interact specifically with the intended mRNA target. This high degree of specificity may make antisense drugs more effective and less toxic than traditional drugs. Beyond antisense, Company scientists have created another technology that exploits their knowledge of RNA. Ibis Biosciences, Inc., a wholly owned subsidiary of Isis, has developed and is commercializing the Ibis T5000 Biosensor System for rapid identification and characterization of organisms.
Location
1896 Rutherford Road
Carlsbad
California
92008-7208
United States of America
Contact
Phone: 760.931.9200
Fax: 760.603.2700
Email: info@isisph.com
News Articles
Isis PharmaGlaxoSmithKline's ISIS-TTR Rx gains US fast-track designation
In what has been a busy newsflow few days for USA-based Isis Pharmaceutical (Nasdaq: ISIS), the company said yesterday that the US Food and Drug administration has granted ISIS-TTRRx fast track desig...
Isis Earns $7.5 Mln Payment From GSK On ISIS-TTR's Phase 2/3 Study Initiation
LONDON (dpa-AFX) - Isis Pharmaceuticals Inc. (ISIS) announced Tuesday that it has earned a $7.5 million milestone payment from GlaxoSmithKline (GSK, GSK.L) related to the initiation of a Phase 2/3...
San Diego Life Sciences Roundup: Isis, Afraxis, Organovo, & More
Developments at Isis and Afraxis were the main events for the local biotech crowd this week, with Isis winning FDA approval for its first-in-class antisense drug and Afraxis licensing all of its drug...
Isis raises $171 million in follow-on
Antisense technology company Isis Pharmaceuticals Inc. (NASDAQ:ISIS) raised $171 million through the sale of 9 million shares at $19 million in a follow-on underwritten by Goldman Sachs; JPMorgan; Sti...
Isis achieves $1.25M milestone for scar treatment
Pfizer will pay Isis Pharmaceuticals a $1.25 million fee following its decision to conduct a midstage trial of Isis' EXC 001, -More-
Roche & Isis Join Forces on Antisense Drug for Huntington’s Disease
San Diego’s Isis Pharmaceuticals (NASDAQ: ISIS) and Roche, the Swiss Pharmaceuticals giant) have formed an alliance to develop new treatments for Huntington’s disease, according to a statement rel...
Isis Pharmaceuticals in partnership with KineMed and CHDI Foundation
KineMed, Isis Pharmaceuticals , and CHDI Foundation are in partnership to utilize KineMed’s translational biomarker platform with Isis’ antisense therapeutic program for Huntington’s disease. Th...
NEW YORK, Jan. 3, 2013 /PRNewswire/ -- Morgan & Morgan announced today that it has begun a securities class action investigation of ISIS Pharmaceuticals, Inc. (ISIS) for potential violations of fe...
Drugs and Medications
Atenolol [Cadila Healthcare Limited]
Atenolol Tablets, USP
Atenolol [Zydus Pharmaceuticals (USA) Inc.]
Atenolol Tablets, USP
Atenolol [State of Florida DOH Central Pharmacy]
Atenolol Tablets, USP
Atenolol [Mutual Pharmaceutical Company, Inc.]
ATENOLOL TABLETS USP
PubMed Articles
Association of stimuli at long intervals in conditioned odor aversion.
Rats learn to avoid a tasteless odorized solution if they experience visceral malaise after consuming it. This phenomenon is referred as Conditioned Odor Aversion (COA). It is widely accepted that an...
Dehydrocholic acid was identified as a selective streptavidin binder from a PNA-tagged library. Isothermal calorimetry titration measurements showed this interaction to be entropically driven. Peptide...
Curved apparent motion induced by amodal completion.
We investigated whether amodal completion can bias apparent motion (AM) to deviate from its default straight path toward a longer curved path, which would violate the well-established principle that A...
Auditory repetition enhancement at short interstimulus intervals for frequency-modulated tones.
Frequency-modulated (FM) sweeps are important components of most natural sounds. To examine the processing of these stimuli we applied a two-tone paradigm. Repeated stimulus presentation usually leads...
We report the synthesis of a nucleic acid-encoded carbohydrate library, its combinatorial self-assembly into 37 485 pairs and a screen against DC-SIGN leading to the identification of consensus liga...
Clinical Trials
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of ISIS 353512, to evaluate the blood concentration and rate elimination of ISIS 353512 fr...
Dose-Escalating Safety Study in Subjects on Stable Statin Therapy
The aim of this study is to assess the safety of varying doses of ISIS 301012 in subjects on Stable statin therapy.
The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 as add-on therapy in subjects with Heterozygous Familial Hypercholesterolemia
To evaluate the efficacy and safety of ISIS 2922 in AIDS patients with Cytomegalovirus ( CMV ) retinitis who are unresponsive or intolerant to ganciclovir and/or foscarnet but are otherwis...
Purpose of this study is to evaluate the safety, tolerability, antiviral activity, and pharmacokinetic behavior of ISIS 14803 administered for up to 12 weeks by intravenous infusions in pa...
Companies
Isis Innovation is the technology transfer company of the University of Oxford, commercialising the research generated by University researchers and owned by the University.Isis Innovation Ltd is a wh...
Isis Parenting is the nationâs leading provider of prenatal and early parenting education. Isis partners with leading healthcare institutions to offer over their patients ove...
Excaliard Pharmaceuticals, Inc.
Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...
Isis Pharmaceuticals, Inc. is a leading drug discovery and development company, focused exclusively on the therapeutic target, RNA. Founded in 1989, Isis' mission is to develop products from its RNA-b...
More Information about "Isis Pharmaceuticals" on BioPortfolio
We have published hundreds of Isis Pharmaceuticals news stories on BioPortfolio along with dozens of Isis Pharmaceuticals Clinical Trials and PubMed Articles about Isis Pharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Isis Pharmaceuticals Companies in our database. You can also find out about relevant Isis Pharmaceuticals Drugs and Medications on this site too.
